Literature DB >> 28320083

Xiaoaiping combined with cisplatin can inhibit proliferation and invasion and induce cell cycle arrest and apoptosis in human ovarian cancer cell lines.

Ai-Wen Zheng1, Ya-Qing Chen1, Jing Fang1, Ying-Li Zhang1, Dong-Dong Jia2.   

Abstract

PURPOSE: The aim of the present study was utilizing Xiaoaiping as a single agent or combined with cisplatin to study its effect on the ovarian cancer cells (HO-8910 and HO-8910PM cells) in tumor cell proliferation, cell apoptosis, cell cycle distribution and cell invasion and migration.
METHODS: Both HO-8910 and HO-8910PM cell lines were treated with Xiaoaiping injection, cisplatin or combination. Effects on the cell viability and apoptosis induction were estimated using the Cell counting Kit-8 assay and Annexin V-FITC/Propidium Iodide staining. The distribution of cells in different phases of the cell cycle was assayed using flow cytometry analysis. The effects of Xiaoaiping on the inhibition of cell invasion and migration were researched with Transwell cell migration.
RESULTS: Both Xiaoaiping and cisplatin significantly decreased the HO-8910 cell survival versus control arm. Combination treatment showed a higher cytotoxicity to cells in vitro than Xiaoaiping and cisplatin alone. An increase in the G0/G1 phase fraction in HO-8910 cells treated with either Xiaoaiping or cisplatin alone was evident when compared to the fraction in control arm. Compared to the effects of treatment with either agent alone, combination treatment significantly increased the fraction of cells in G0/G1 phase. The HO-8910 cell lines treated with cisplatin demonstrated a significant increase of apoptotic cell rate compared to untreated cell lines. The rate of apoptosis in combined treatment group was significantly higher than that of the single agent treatment groups. A significant reduction in the number of invading cells was observed for Xiaoaiping-treated HO-8910 cells compared with the control group. However, cisplatin did not significantly induce the migration of cells versus untreated cells. Combination of Xiaoaiping and cisplatin significantly suppressed cell invasion and migration versus single-drug treatment in HO-8910 cells. The results of HO-8910PM cells were similar with HO-8910 cells in all tests.
CONCLUSIONS: In summary, our results showed that Xiaoaiping as a single agent or combined with cisplatin could induce cell cycle arrest, cause apoptosis and necrosis in ovarian cancer cells, and inhibit cell invasion and migration. The present study also laid a foundation for further investigation involving molecular mechanism. Above all, it may provide a novel therapeutic regimen for ovarian cancer.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Apoptosis; Cell cycle arrest; Cell invasion; Ovarian cancer; Proliferation; Xiaoaiping

Mesh:

Substances:

Year:  2017        PMID: 28320083     DOI: 10.1016/j.biopha.2017.03.012

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  13 in total

1.  Deregulated expression and subcellular localization of CPSF6, a circRNA-binding protein, promote malignant development of esophageal squamous cell carcinoma.

Authors:  Shichao Guo; Guangchao Wang; Zitong Zhao; Dan Li; Yongmei Song; Qimin Zhan
Journal:  Chin J Cancer Res       Date:  2022-02-28       Impact factor: 5.087

2.  Network Meta-Analysis of Chinese Herbal Injections Plus the FOLFOX Regimen for the Treatment of Colorectal Cancer in China.

Authors:  Dan Zhang; Jiarui Wu; Xiaojiao Duan; Kaihuan Wang; Mengwei Ni; Shuyu Liu; Xiaomeng Zhang; Bing Zhang; Yi Zhao
Journal:  Integr Cancer Ther       Date:  2019 Jan-Dec       Impact factor: 3.279

3.  In Vivo Study on the Effects of Xiaoaiping on the Stemness of Hepatocellular Carcinoma Cells.

Authors:  Jing Zhan; Liang-Liang Shi; Yan Wang; Bai Wei; Sheng-Li Yang
Journal:  Evid Based Complement Alternat Med       Date:  2019-06-23       Impact factor: 2.629

4.  Xiao-ai-ping injection adjunct with platinum-based chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis.

Authors:  Fanchao Feng; Jingyi Huang; Zhichao Wang; Jiarui Zhang; Di Han; Qi Wu; Hailang He; Xianmei Zhou
Journal:  BMC Complement Med Ther       Date:  2020-01-13

5.  Tenacissoside H Induces Apoptosis and Inhibits Migration of Colon Cancer Cells by Downregulating Expression of GOLPH3 Gene.

Authors:  Zhong-Shi Hong; Hai-Bin Zhuang; Cheng-Zhi Qiu; Ze-Sheng Shi; Chun-Xiao Wang; Zhi-Chuan Chen; Jian-Peng Pan
Journal:  Evid Based Complement Alternat Med       Date:  2020-05-07       Impact factor: 2.629

6.  Xiaoaiping injection as adjunct therapy for patients with advanced esophageal carcinoma: A protocol for a systematic review and meta-analysis.

Authors:  Zhen Liu; Yanling Dong; Meili Zhu; Ying Mu; Lemei Chen
Journal:  Medicine (Baltimore)       Date:  2020-06-26       Impact factor: 1.817

7.  Xiao-Ai-Ping Injection Enhances Effect of Paclitaxel to Suppress Breast Cancer Proliferation and Metastasis via Activating Transcription Factor 3.

Authors:  Junjun Chen; Xiangqi Zhang; Xiao Xiao; Yawei Ding; Wei Zhang; Meizhi Shi; Jiao Yang; Ying Liu; Yonglong Han
Journal:  Integr Cancer Ther       Date:  2020 Jan-Dec       Impact factor: 3.279

8.  The Effect of Okra (Abelmoschus esculentus (L.) Moench) Seed Extract on Human Cancer Cell Lines Delivered in Its Native Form and Loaded in Polymeric Micelles.

Authors:  Watcharaphong Chaemsawang; Weerapong Prasongchean; Konstantinos I Papadopoulos; Garnpimol Ritthidej; Suchada Sukrong; Phanphen Wattanaarsakit
Journal:  Int J Biomater       Date:  2019-10-21

9.  Efficacy and safety of Xiaoaiping injection for liver cancer: A protocol for systematic review and meta-analysis.

Authors:  Daorui Hou; Jian Xiong; Ya Li; Yahui Peng; Lu Xiong
Journal:  Medicine (Baltimore)       Date:  2020-08-28       Impact factor: 1.817

10.  Efficacy and safety of Xiaoaiping injection for breast cancer: A protocol for systematic review and meta-analysis.

Authors:  Daorui Hou; Jian Xiong; Yahui Peng; Ya Li; Lu Xiong
Journal:  Medicine (Baltimore)       Date:  2020-08-28       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.